STAT Plus: What we learned about the digital pharmacy business from Hims & Hers filing to go public

Over the past few years, a pack of sleek, marketing-savvy startups have sprouted up offering online prescriptions for drugs for common medical conditions. But even as they’ve touted their rapid growth, they’ve provided few details about their financials — which they’re entitled to do, as privately held companies.

That changed on Thursday, when San Francisco-based Hims & Hers, one of the leaders in the online pharmacy space, filed paperwork with the Securities and Exchange Commission to go public — shining light for the first time on the detailed financials of a business in an emerging sector that’s transformed the way many people get their medications.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.